TY - JOUR PY - 2022// TI - Association of metformin use with fracture risk in type 2 diabetes: a systematic review and meta-analysis of observational studies JO - Frontiers in endocrinology A1 - Wang, Yining A1 - Yu, Liming A1 - Ye, Zhiqiang A1 - Lin, Rui A1 - Sun, Antonia RuJia A1 - Liu, Lingna A1 - Wei, Jinsong A1 - Deng, Feifu A1 - Zhong, Xiangxin A1 - Cui, Liao A1 - Li, Li A1 - Liu, Yanzhi SP - e1038603 EP - e1038603 VL - 13 IS - N2 - AIMS: Increasing evidence suggests that metformin can affect bone metabolism beyond its hypoglycemic effects in diabetic patients. However, the effects of metformin on fracture risk in type 2 diabetes mellitus (T2DM) patients remain unclear. A systematic review and meta-analysis were performed in this study to evaluate the association between metformin application and fracture risk in T2DM patients based on previous studies published until June 2021.

METHODS: A systematic search was performed to collect publications on metformin application in T2DM patients based on PubMed, Embase, Cochran, and Web of Science databases. Meta-analysis was performed by using a random-effects model to estimate the summary relative risks (RRs) with 95% confidence intervals (CIs). Subgroup analyses based on cohort/case-control and ethnicity and sensitivity analyses were also performed.

RESULTS: Eleven studies were included in the meta-analysis.

RESULTS demonstrated metformin use was not significantly associated with a decreased risk of fracture (RR, 0.91; 95% CI, 0.81-1.02; I(2 =) 96.8%). Moreover, metformin use also demonstrated similar results in subgroup analyses of seven cohort studies and four case-control studies, respectively (RR, 0.90; 95% CI, 0.76-1.07; I(2 =) 98.0%; RR, 0.96; 96% CI, 0.89-1.03; I(2 =) 53.7%). Sensitivity analysis revealed that there was no publication bias.

CONCLUSION: There was no significant correlation between fracture risk and metformin application in T2DM patients. Due to a limited number of existing studies, further research is needed to make a definite conclusion for clinical consensus.

Language: en

LA - en SN - 1664-2392 UR - http://dx.doi.org/10.3389/fendo.2022.1038603 ID - ref1 ER -